EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data

Corinne Young, Lydia Y Lee iD, Kristi K DiRocco iD, Guillaume Germain iD, Jacob Klimek, François Laliberté iD, Dominique Lejeune, Stephen G Noorduyn iD, Rosirene Paczkowski iD

Advances in Therapy · 2025

DOI: 10.1007/s12325-024-03055-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Therapy, 2025. Verfasst von Corinne Young und 8 weiteren Autor:innen. Beteiligte Einrichtung: Association of Pulmonary Advanced Practice Providers and Clinical Services, Colorado Springs, CO, USA. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Bronchodilator Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Previously, adherence and persistence to treatment have been shown to improve outcomes among patients with chronic obstructive pulmonary disease (COPD). This study aimed to evaluate adherence and persistence to single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI; one inhalation, once-daily) compared with budesonide/glycopyrrolate/formoterol fumarate (BUD/GLY/FOR; two inhalations, twice-daily) among patients with COPD in the USA. METHODS: This retrospective weighted cohort study used claims data from the IQVIA PharMetrics® Plus Database from October 1, 2019 to March 31, 2023, to identify patients with COPD newly initiating FF/UMEC/VI or BUD/GLY/FOR. Index date was the first pharmacy claim for FF/UMEC/VI or BUD/GLY/FOR on or after October 1, 2020. The longest follow-up period was 12 months. Inverse probability of treatment weighting was used to balance baseline characteristics between cohorts. Adherence was measured as mean proportion of days covered (PDC); the proportion of patients with PDC ≥ 0.5 and PDC ≥ 0.8 was also assessed. Persistence was assessed as time to treatment discontinuation using Kaplan-Meier rates. RESULTS: Overall, 8912 and 2685 patients were included in the FF/UMEC/VI and BUD/GLY/FOR cohorts, respectively. After weighting, mean age and proportion of patients with Medicare Advantage insurance was 64.62 years and 40.0% in the FF/UMEC/VI cohort and 63.96 years and 36.1% in the BUD/GLY/FOR cohort. At 6 months post-index, mean PDC was greater in the FF/UMEC/VI versus the BUD/GLY/FOR cohort (0.65 versus 0.59; P < 0.001). A significantly greater proportion of patients in the FF/UMEC/VI versus the BUD/GLY/FOR cohort had PDC ≥ 0.8 (45.6% versus 34.5%; P < 0.001) and PDC ≥ 0.5 (71.8% versus 64.3%; P < 0.001). Results were consistent at 12 months post-index. When a 30-day gap was used to define treatment discontinuation, the FF/UMEC/VI cohort had statistically significantly greater treatment persistence versus the BUD/GLY/FOR cohort at all time points. CONCLUSION: In this study, patients initiating FF/UMEC/VI had significantly greater adherence and persistence to treatment than patients initiating BUD/GLY/FOR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary Disease, Chronic ObstructiveBronchodilator AgentsHumansMaleFemaleUnited StatesRetrospective StudiesAgedMiddle AgedQuinuclidinesMedicare Part CAdministration, InhalationGlycopyrrolateDrug CombinationsBudesonideBenzyl AlcoholsChlorobenzenesFormoterol FumarateDrug Therapy, CombinationInsurance Claim ReviewNebulizers and VaporizersAndrostadienes

Stichwörter der Autor:innen

AdherenceBUD/GLY/FORCOPDFF/UMEC/VIMedicare AdvantagePersistenceReal-world evidenceSingle-inhaler triple therapy

Substanzen

GSK573719QuinuclidinesBronchodilator AgentsvilanterolGlycopyrrolateDrug CombinationsBudesonideBenzyl AlcoholsChlorobenzenesFormoterol Fumarate

Autor:innen und Institutionen

  • Association of Pulmonary Advanced Practice Providers and Clinical Services, Colorado Springs, CO, USA.
  • US Value Evidence and Outcomes, R&D Global Medical, GSK, Collegeville, PA, 19426-0989, USA.
  • US Medical Affairs, GSK, Collegeville, PA, USA.
  • Groupe d'analyse, Ltée, Montréal, QC, Canada.
  • Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
  • Value Evidence and Outcomes, R&D Global Medical, GSK, Mississauga, ON, Canada.

ORCID-Profile: Lydia Y Lee, Kristi K DiRocco, Guillaume Germain, François Laliberté, Stephen G Noorduyn, Rosirene Paczkowski

Förderung

  • GSK

Zitieren

APA

Young, C., Lee, L. Y., DiRocco, K. K., Germain, G., Klimek, J., Laliberté, F., Lejeune, D., Noorduyn, S. G., & Paczkowski, R. (2025). Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data. Advances in Therapy. https://doi.org/10.1007/s12325-024-03055-w

Vancouver

Young C, Lee LY, DiRocco KK, Germain G, Klimek J, Laliberté F, et al. Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data. Advances in Therapy. 2025. doi:10.1007/s12325-024-03055-w

BibTeX
@article{Young2025,
  author = {Young, Corinne and Lee, Lydia Y and DiRocco, Kristi K and Germain, Guillaume and Klimek, Jacob and Laliberté, François and Lejeune, Dominique and Noorduyn, Stephen G and Paczkowski, Rosirene},
  title = {Adherence and Persistence with Single-Inhaler Triple Therapy Among Patients with COPD Using Commercial and Medicare Advantage US Health Plan Claims Data},
  journal = {Advances in Therapy},
  year = {2025},
  doi = {10.1007/s12325-024-03055-w}
}
Kostenlos starten →